文献速递前列腺癌

MRI定义的前列腺特异抗原密度显著改善活检临床显著前列腺癌风险预测

Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
PubMed 文献 · Urology · 2018-12-20

比较MRI定义PSA密度、PSA和PCPT风险计算器单独或联合PI-RADS分类预测活检临床显著前列腺癌的效能。结果显示MRI定义PSA密度模型AUC为0.77,显著优于PSA(0.66)和PCPT(0.70);联合PI-RADS后AUC达0.80,仍显著优于联合PSA(0.75)和联合PCPT(0.76)。

要点

  • MRI定义PSA密度预测临床显著前列腺癌的AUC为0.77,优于PSA和PCPT。
  • 联合PI-RADS分类后,MRI定义PSA密度模型AUC提升至0.80。
  • MRI可同时评估前列腺体积,辅助计算PSA密度改善风险分层。

核心结论

  • 除PI-RADS分类外,活检前多参数MRI提供的前列腺体积可计算MRI定义PSA密度,显著改善活检临床显著前列腺癌的风险判别。

主要发现

  • MRI定义PSA密度模型AUC为0.77,显著优于PSA模型AUC 0.66(P < .01)和PCPT模型AUC 0.70(P < .01)。
  • 联合MRI解释(PI-RADS分类)后,MRI定义PSA密度模型AUC为0.80,显著优于PSA联合MRI模型AUC 0.75(P < .01)和PCPT联合MRI模型AUC 0.76(P = .01)。

关键数值与推荐

  • MRI定义PSA密度单独预测临床显著前列腺癌的AUC为0.77。
  • PSA单独预测的AUC为0.66,PCPT风险计算器预测的AUC为0.70。
  • MRI定义PSA密度联合PI-RADS分类的AUC为0.80,PSA联合PI-RADS为0.75,PCPT联合PI-RADS为0.76。

临床怎么用

  • 活检前可借助多参数MRI测量的前列腺体积计算MRI定义PSA密度,联合PI-RADS分类提升临床显著前列腺癌的风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the predictive value of magnetic resonance imaging (MRI)-defined prostate-specific antigen (PSA) density and MRI interpretation for the detection of clinically significant prostate cancer (PCa). METHODS: We retrospectively reviewed our institutional database of men who received prostate MRI prior to biopsy at our institution between September 2014 and December 2016, excluding those on active surveillance (n = 372). Logistic regression models to predict clinically significant PCa on biopsy were developed using (1) MRI-defined PSA density; (2) PSA alone; and (3) the Prostate Cancer Prevention Trial (PCPT) risk calculator. Additional logistic regression models were then generated by combining the previous clinical variables with MRI interpretation (ie, prostate imaging reporting and data system [PI-RADS] classification): (1) MRI-defined PSA density + MRI interpretation; (2) PSA + MRI interpretation; and (3) PCPT + MRI interpretation. Receiving operator characteristic curves for each of the 6 models were generated, and the area under the curves (AUC) were compared. RESULTS: MRI-defined PSA density (AUCPSAD = 0.77) significantly outperformed the PSA (AUCPSA = 0.66, P < .01) and PCPT models (AUCPCPT = 0.70, P < .01). When combined with MRI interpretation (ie, PI-RADS classification), the MRI-defined PSA density model (AUCPSAD + MRI = 0.80) significantly outperformed the PSA (AUCPSA + MRI = 0.75, P < .01) and PCPT models (AUCPCPT + MRI = 0.76, P = .01). CONCLUSION: In addition to the PI-RADS classification, prebiopsy multiparametric magnetic resonance imaging also provides an accurate assessment of prostate volume. By utilizing this additional data to determine MRI-defined PSA density, we find that risk discrimination for clinically significant PCa on biopsy can be significantly improved.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Bhat NR, Vetter JM, Andriole GL, et al. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy. Urology. 2018. PMID: 30580005. doi:10.1016/j.urology.2018.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。